Pfizer Inc. (NYSE:PFE) Stake Boosted by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,458,828 shares of the biopharmaceutical company’s stock after buying an additional 172,602 shares during the period. Pfizer comprises about 2.1% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings, making the stock its 7th biggest position. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Pfizer were worth $64,962,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Pfizer during the 3rd quarter worth $146,481,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Pfizer by 164.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock worth $211,737,000 after purchasing an additional 4,546,809 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in Pfizer by 226.7% during the third quarter. Fisher Asset Management LLC now owns 6,209,907 shares of the biopharmaceutical company’s stock valued at $179,715,000 after acquiring an additional 4,309,076 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.46 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a 50 day moving average of $26.07 and a 200 day moving average of $27.96. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.94 billion, a price-to-earnings ratio of 35.75, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.17) EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.50%. Pfizer’s dividend payout ratio is 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.